Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2009

View Archived Issues

New PI3K inhibitors imparted in recent UCB patent

Roche researchers discover novel GABA-A alpha5 receptor ligands

Recent Roche patents divulge new trace amine receptor 1 ligands

Novel thrombin inhibitors discovered by AstraZeneca researchers

Novel 11beta-HSD1 inhibitors imparted by Taisho for type 2 diabetes

Schering-Plough reflects on Q4 developments

NanoBio develops novel nanoemulsion antimicrobial for cystic fibrosis-related pathogens

Roche divulges new chemokine CCR2 antagonists for cardiovascular disorders

MAGL inhibition may be useful in treating behavioral disorders

MediciNova reaffirms proposal to acquire Avigen

Genentech collaborates with National Cancer Institute on GDC-0449

EntreMed presents initial preclinical and phase I results for ENMD-2076

ViroPharma reports phase III maribavir trial results in bone marrow transplant

MCT1 inhibition blocks hypoxic-oxygenated tumor cell symbiosis and leads to cell death

Inhibitex completes phase I trials of FV-100 and selects HCV compounds for development

Coated magnetic beads capture infectious human influenza viruses

Lundbeck to acquire Ovation

NanoViricides presents update on development of nanoviricide against HSV and adenovirus

AstraZeneca licenses TRI compounds discovered by Mayo Clinic and Virginia Tech

Ligand earns milestone from Schering-Plough on progress of BACE drug for AD

Critical Outcome Technologies reports results from in vitro studies of oncology drug COTI-2

Roche commences tender offer to Genentech

Xoma and Takeda expand antibody technology collaboration

Priligy receives first regulatory approvals for premature ejaculation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...